Table 1.
Description and HLA typing of patients
| ¶Autoantibody titre | HLA typing | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient code | Diagnosis† | Other AI pathologies‡ | Sex | §Age at sampling | §Age at diagnosis | GAD Ab | IA-2 Ab | DRB1* | DQB1* |
| DM1 | DM 1 | – | F | 19 | 19 | 515 | 37 | 04, – | 0302, – |
| DM2 | DM 1 | – | M | 15 | 15 | 9 | <0·20 | 03, 03 | 0201, – |
| DM3 | DM 1 | – | F | 23 | 23 | 58 | 0·20 | 03, 04 | 0201, 0302 |
| DM4 | DM 1 | – | F | 33 | 33 | 160 | 14 | 04, 13 | 0603, 0302 |
| DM5 | DM 1 | – | F | 25 | 25 | 600 | 5·20 | 03, 13 | 0201, 0609 |
| DM6 | DM 1 | – | F | 24 | 24 | 200 | 33·80 | 03, 07 | 0201, 0202 |
| DM7 | DM 1 | – | M | 30 | 30 | 27 | 0·86 | 03, 04 | 0201, 0302 |
| DM8 | DM 1 | – | F | 18 | 18 | 18 | 0·30 | 03, 03 | 0201, 0201 |
| DM9 | DM 1 | – | M | 16 | 16 | 54 | 4·80 | 04, 03 | 0302, 0201 |
| DM12 | APS | GD, VI | F | 61 | 60 | 1100 | 3·90 | 16, 03 | 0502, 0201 |
| DM13 | APS | VI, HT | F | 61 | 59 | 30000 | 0·20 | 04, 07 | 0202, 0302 |
| DM14 | APS | TPO, GPC | F | 42 | 38 | 1850 | <0·20 | 15, 04 | 0302, 0602 |
| DM16 | APS | TPO, GPC | F | 37 | 34 | 4000 | 1·20 | 03, 07 | 0201, 0202 |
| DM17 | APS | GD | F | 27 | 26 | 1100 | 0·15 | 01, 03 | 0501, 0201 |
| DM18 | APS | Vl, HT | F | 34 | 18 | 5200 | 0·3 | 01, 04 | 0501, 0301 |
| DM20 | APS | TPO | F | 24 | 18 | 1300 | 0·25 | 03, 04 | 0302, 0201 |
| DM21 | APS | VI, TPO, GPC | F | 22 | 8 | 5200 | 0·35 | 03, 04 | 0201, 0302 |
| SMS1¶¶ | SMS | DM 1 | F | 56 | 46 | 42000 | 0, 01 | 03, 08 | 0402, 0201 |
| SMS2 | SMS | VI | F | 77 | 72 | 67000 | 0, 15 | 13, 16 | 0603, 0502 |
| SMS3¶¶ | SMS | GD | F | 66 | 60 | 31333 | 0, 02 | 04, 03 | 0302, 0201 |
| SMS4 | SMS | DM 1 | F | 62 | 61 | 8700 | 0, 25 | 03, 07 | 0201, 0202 |
| SMS5 | SMS | DMI, HT | F | 38 | 37 | 4900 | 0, 03 | 03, 07 | nd |
| ACA1 | CAPA | DM 1 | F | 53 | 53 | 2300 | 2·90 | 03, 04 | 0302, 0201 |
| ACA2§§ | CAPA | DM 1 | F | 59 | 51 | 14000 | 0·10 | 01, 12 | 0301, 0501 |
| ACA3§§ | CAPA | DM 1, PA | F | 79 | 74 | 70000 | 0·15 | 01, 13 | 0501, 0604 |
| ACA4 | CAPA | HT | F | 40 | 39 | 22400 | 9·90 | 04, 04 | 0301, 0302 |
| ACA5§§ | CAPA | DM 1 | F | 63 | 61 | 39500 | 0·20 | 03, 07 | 0202, 0201 |
| ACA6 | CAPA | DM 1, GD, MG | F | 48 | 46 | 100000 | 0·25 | nd | 0603, 0503 |
| C1 | Control A | – | M | 17 | – | <0·20 | 0·10 | 15, 07 | nd |
| C2 | Control A | – | M | 14 | – | 0·20 | 0·15 | 03, – | nd |
| C3 | Control A | – | M | 19 | – | 0·30 | 0·20 | 07, 11 | 0202, 0301 |
| C4 | Control A | – | F | 21 | – | 0·40 | 0·25 | 08, 13 | 0202, – |
| C5 | Control A | – | F | 28 | – | <0·20 | 0·30 | 14, 17 | nd |
| C6 | Control A | – | F | 23 | – | 0·25 | 0·35 | 04, 15 | 0302, 0602 |
| C7 | Control A | – | M | 16 | – | 0·35 | 0·32 | 01, 13 | 0301, 0501 |
| C8 | Control A | – | F | 26 | – | 0·45 | 0·12 | 04, 07 | nd |
| C9 | Control A | – | F | 16 | – | <0·20 | 0·28 | 16, 12 | nd |
| C10 | Control B | – | F | 57 | – | <0·20 | nd | nd | nd |
| C11 | Control B | – | F | 59 | – | <0·20 | nd | nd | nd |
| C12 | Control B | – | F | 64 | – | <0·20 | nd | 07, 13 | 0202, 0603 |
| C13 | Control B | – | F | 53 | – | <0·20 | nd | nd | nd |
| C14 | Control B | – | F | 53 | – | <0·20 | nd | 03, 11 | 0201, 0301 |
| C15 | Control B | – | F | 57 | – | <0·20 | nd | 11, 13 | 0301, 0602 |
†
DM 1, type 1 diabetes mellitus; APS, type 2 autoimmune polyendocrine syndrome; SMS, stiff-man syndrome; CAPA, cerebellar ataxia associated with polyendocrine autoimmunity; Control A, control donors with 20 years average age; Control B, control donors with 57 years average age.
‡
AI, autoimmune; HT, Hashimoto's thyroiditis; GD, Graves’ disease; VI, vitiligo; MG, myastenia gravis; PA, pernicious anaemia; TPO, antibodies to thyroid peroxidase; GPC, antibodies to gastric parietal cells.
§
Age in years.
¶
U/ml. nd, not done.
¶¶
described in reference [37].
§§
described in reference [11].